← All trials
NCT05903690
Early Phase 1Interventional
Exploratory trials, involving very limited human exposure, with no therapeutic or diagnostic intent (e.g., screening studies, microdose studies).
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 22, 2023
- Primary completion
- Feb 28, 2024
- Completion date
- Feb 28, 2024
- First posted
- Jun 15, 2023
- Last posted
- Jun 15, 2023
- Enrollment
- 6
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Capital Medical UniversityLead sponsor
- Capital Medical UniversityOverall official - principal investigator
- Capital Medical UniversityReponsible party - principal investigator
- Capital Medical UniversitySponsor investigator
- Ractigen Therapeutics.Collaborator
- Capital Medical UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.